Megan Smith. Kate Goodheart. Claudia Fryer. Tomas Balcytis. Peter Wilmshurst. Patricia Murray.
Contact The Author
All content is freely available without charge to users or their institutions. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission of the publisher or the author. Articles published in the journal are distributed under a http://creativecommons.org/licenses/by/4.0/.
An analysis of the UK’s commercial stem cell clinics
Megan Smith. Kate Goodheart. Claudia Fryer. Tomas Balcytis. Peter Wilmshurst. Patricia Murray.
Paper
Commercial stem cell clinics in the UK are offering therapies of unproven efficacy that have the potential to cause harm. Marketing information used to advertise the therapies is often misleading and prices can be extortionate. Most so-called ‘stem cell’ therapies are currently exempt from regulations. This needs to be addressed urgently to stop patients from being subjected to financial, physical or psychological harm. To address these problems, we have made several recommendations, which include better education for healthcare professionals, concerted action by regulators and new legislation.
